title: Technology evaluation: SB-485232, GlaxoSmithKline.
abstract: GlaxoSmithKline (formerly SmithKline Beecham), under license from Hayashibara, is developing SB-485232, a recombinant human interleukin-18 cancer immunotherapy for the potential treatment of immunologically sensitive cancers, including melanoma and renal cell cancer. The compound is currently undergoing phase II clinical trials.
authors.affiliation: The Medical University of Warsaw, Department of Immunology, Center of Biostructure Research, Warsaw, Poland. jgolab@ib.amwaw.edu.pl
authors.forename: Jakub
authors.initials: J
authors.lastname: Golab
authors.forename: Tomasz
authors.initials: T
authors.lastname: Stoklosa
mesh_terms: D000276:Adjuvants, Immunologic / Q000235:genetics / Q000378:metabolism / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000818:Animals; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D020382:Interleukin-18 / Q000235:genetics / Q000378:metabolism / Q000493:pharmacokinetics / Q000627:therapeutic use*; D051379:Mice; D009369:Neoplasms / Q000188:drug therapy*; D011994:Recombinant Proteins / Q000235:genetics / Q000378:metabolism / Q000493:pharmacokinetics / Q000627:therapeutic use*
chemical_list: D000276:Adjuvants, Immunologic; D020382:Interleukin-18; D011994:Recombinant Proteins